Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of HGP1201 (Tadalafil) and HGP0904 (Amlodipine) in Healthy Males
NCT02243319Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Sep 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tadalafil and amlodipine in erectile dysfunction (ED), benign prostatic hyperplasia (BPH) and hypertension (HTN) (6 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at Steady State at Day 12 and Area Under the Curve over the Dosing Interval at Steady State at Day 12. Started Sep 2014; status: completed.
02
Drugs
tadalafilamlodipine
03
Conditions
erectile dysfunction (ED)benign prostatic hyperplasia (BPH)hypertension (HTN)
Beyond the preview
Go deeper on NCT02243319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02243319.